Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study.
Medicine (Baltimore)
; 100(12): e25110, 2021 Mar 26.
Article
in En
| MEDLINE
| ID: mdl-33761674
ABSTRACT
ABSTRACT Oral direct-acting antiviral (DAA) treatment leads to >95% sustained virological response (SVR) and could be clinically useful in regression of liver fibrosis in chronic hepatitis C virus (HCV) infection. We evaluated if ledipasvir/sofosbuvir or sofosbuvirâ+âribavirin is associated with regression of fibrosis in HCV patients who achieved SVR.In this prospective cohort study performed at 3 sites in Japan, patients with genotype 1 and genotype 2 were given standard treatment of ledipasvir 90âmg/sofosbuvir 400âmg and sofosbuvir 400âmgâ+â200-1000âmg/day ribavirin, respectively, for 12âweeks. Liver fibrosis was assessed using Mac-2-binding protein glycosylation isomer (M2BPGi) and other fibrosis markers (platelet count, Fib-4 index, liver stiffness measurement [LSM]) in patients who achieved SVR.A total of 98.1% of (nâ=â101/103) patients in genotype 1 cohort and 100% (nâ=â16/16) in the genotype 2 cohort achieved SVR12. Based on per-protocol analysis, M2BPGi levels showed a significant decrease (-2.2â cut-off index [COI], Pâ<â.0001) at week 48 after treatment initiation. Forty-three patients showed a significant decrease in Fib-4 index (-1.2, Pâ<â.0001), and 44 patients showed improvement in LSM (-5.9âkPa, Pâ<â.0001).Achievement of SVR after antiviral therapy was associated with fibrosis regression. M2BPGi correlated well with LSM at week 48 after treatment initiation, supporting the sustainable benefit of HCV therapy.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ribavirin
/
Benzimidazoles
/
Hepacivirus
/
Hepatitis C, Chronic
/
Fluorenes
/
Sofosbuvir
/
Liver Cirrhosis
Type of study:
Guideline
/
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Medicine (Baltimore)
Year:
2021
Document type:
Article